Lexaria Bioscience Corp (LEXX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 08/31
(Values in U.S. thousands)
| 02-2024 | 11-2023 | 08-2023 | 05-2023 | 02-2023 | |
| Sales | 145 | 151 | 15 | 93 | 20 |
| Cost of Goods | N/A | 5 | N/A | 13 | 3 |
| Gross Profit | 145 | 147 | 15 | 80 | 17 |
| Operating Expenses | 813 | 1,290 | 1,147 | 2,477 | 1,344 |
| Operating Income | -668 | -1,139 | -1,131 | -2,384 | -1,324 |
| Other Income | 15 | -46 | -118 | 0 | 13 |
| Pre-tax Income | -653 | -1,185 | -1,249 | -2,384 | -1,311 |
| Net Income Continuous | -653 | -1,185 | -1,249 | -2,384 | -1,311 |
| Minority Interests | -3 | -6 | -10 | -12 | -13 |
| Net Income | $-650 | $-1,179 | $-1,239 | $-2,372 | $-1,298 |
| EPS Basic Total Ops | -0.06 | -0.13 | -0.12 | -0.37 | -0.22 |
| EPS Basic Continuous Ops | -0.06 | -0.13 | -0.13 | -0.37 | -0.22 |
| EPS Diluted Total Ops | -0.06 | -0.13 | -0.12 | -0.37 | -0.22 |
| EPS Diluted Continuous Ops | -0.06 | -0.13 | -0.13 | -0.37 | -0.22 |
| EPS Diluted Before Non-Recurring Items | -0.06 | -0.13 | -0.12 | -0.37 | -0.22 |
| EBITDA(a) | $-652 | $-1,110 | $-1,061 | $-2,359 | $-1,299 |